Recently, IT effectiveness was shown to correlate positively with the number of CD8+ lymphocytes and negatively with the number of FOXP3+ tumor-infiltrating lymphocytes in patients who acquired resistance to EGFR-TKIs [52]. The gene discussed is EGFR; the disease is neoplasm.